Loading
A phase 3 trial of Xembify in chronic lymphocytic leukaemia and non-Hodgkin lymphoma, run by Grifols Therapeutics LLC, now recruiting.
A Study to Evaluate Efficacy, Safety, and PK of XEMBIFY®+Standard Medical Treatment (SMT) Compared to Placebo+SMT to Prevent Infections in Participants With HGG and Recurrent or Severe Infections Associated With B-cell Chronic Lymphocytic Leukemia, Multiple Myeloma, and Non-Hodgkin Lymphoma is a phase 3 interventional study registered as NCT05645107 by Grifols Therapeutics LLC, with 386 participants planned, started 2022-12-26 and due to reach its primary completion in 2029-08. Interventions recorded: Xembify and Placebo.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares Grifols, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Chronic lymphocytic leukaemia, Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Shares Non-Hodgkin lymphoma (all types) and the tag pipeline.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/